Study Supports HPV Self-Testing for Cervical Cancer Screening
Medically reviewed by Drugs.com.
By Dennis Thompson HealthDay Reporter
TUESDAY, Dec. 17, 2024 -- A self-administered test can help empower women in identifying risks for cervical cancer.
A new study published Dec. 12 in the journal PLOS Medicine shows the self-test for human papillomavirus (HPV) infection accurately identified women who either had cervical cancer or precancerous cells in their cervix.
"About 40% of women in our high-risk group had been diagnosed with the severe cervical precancer or cancer that requires treatment,” said lead researcher Jiayao Lei, an assistant professor of medical epidemiology and biostatistics at the Karolinska Institute in Sweden.
“Therefore, our recommendation for the future is that this group be referred directly for further investigation with colposcopy [a medical procedure typically performed following abnormal Pap smear results]," Lei added in an institute news release.
These results come roughly a week after a leading panel of preventive medicine experts decided to recommend that women 30 and older should have the option of collecting their own vaginal samples for testing, in lieu of a complete pelvic exam.
“Women who would be more comfortable collecting their HPV test sample themselves can now do so,” Dr. Esa Davis, a member of the U.S. Preventive Services Task Force (USPSTF), said in a release announcing the new guidance. “We hope that this new, effective option helps even more women get screened regularly.”
The USPSTF guidance follows the U.S. Food and Drug Administration's approval of a self-testing kit for cervical cancer last May. That test should be repeated every five years from age 30 until 65, when most women can stop screening, the task force said.
For the new study, researchers analyzed data from 855 women with a positive HPV self-test. They then sorted the women into high-, medium- or low-risk groups based on the type of HPV they had and how much virus was present in their self-test.
They found that a little more than 8% of these women had either cancer or precancerous cells -- about two out of five women in the high-risk HPV group.
On the other hand, more than half who tested positive fell into the low-risk group, with an overall 4% likelihood of being diagnosed with severe cervical pre-cancer or full-fledged cervical cancer within the next year, researchers said.
"We consider it would be safe for the low-risk group to be retested after 12 months," senior researcher Peter Sasieni, a professor at Queen Mary University of London, said. “The moderate-risk group should be encouraged to get tested by clinicians.”
The research team plans to perform a larger-scale study based on self-tests in Sweden in the future.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-12-18 00:00
Read more
- FDA Approves Symbravo (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults
- Gender-Affirming Medication Use Rare in U.S. Transgender Adolescents From 2018 to 2022
- Zolendrate (Reclast) Lowers Fracture Risk in Early Postmenopausal Women
- Cancer Deaths Dropping Despite Rise in New Cases
- Risk for All-Cause Mortality Lower With High Muscle Strength, Fitness in Cancer
- ART Pregnancies Have Higher Exposure to Teratogenic Medications
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions